Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study

Show other versions (1)
Bibliographic Details
Main Authors: M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137920302248

Internet

http://www.sciencedirect.com/science/article/pii/S2531137920302248

Similar Items